secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2026-05-12T20:05:16+00:00
Accession:  0001193125-26-219361
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics reports Q1 2026 results; cash $23.9M, BDC-4182 data expected Q3 2026
--------------------------------------------------------------------------------

- Initial clinical data from BDC-4182 Phase 1/2 study for gastric/gastroesophageal cancer anticipated in Q3 2026.
- Cash balance of $23.9M as of March 31, 2026; expected to fund operations into 2027, including dose-escalation completion.
- Q1 2026 loss from operations $7.6M vs $12.1M in Q1 2025; R&D expense down to $4.8M from $9.5M.
- Two next-generation ISAC programs (CEA and PD-L1) on hold pending BDC-4182 proof-of-concept.
- Collaboration revenue fell to $26,000 in Q1 2026 from $1.2M in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000119312526219361/0001193125-26-219361-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000119312526219361/bolt-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-219361

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer